What's new

Human medicines European public assessment report (EPAR): Kisunla, donanemab, Status: Opinion under re-examination

Human medicines European public assessment report (EPAR): Kisunla, donanemab, Status: Opinion under re-examination

Apr 11, 2025 - 11:53
 0
Human medicines European public assessment report (EPAR): Kisunla, donanemab, Status: Opinion under re-examination
Human medicines European public assessment report (EPAR): Kisunla, donanemab, Status: Opinion under re-examination
Read More

Tags:

Previous Article

UK SME manufacturers see disappointing end to 2024: Unleashed

Next Article

Four Republican senators urge ‘stable’ approach to renewables tax credits

Related Posts

Worksharing: questions and answers

Worksharing: questions and answers

Feb 18, 2025  0

Human medicines European public assessment report (EPAR): Veoza, fezolinetant, Date of authorisation: 07/12/2023, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 14, 2025  0

Human medicines European public assessment report (EPAR): Lantus, insulin glargine, Date of authorisation: 09/06/2000, Revision: 42, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0